胰腺癌的免疫疗法——克服反应障碍
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.
作者信息
Rosenberg Ari, Mahalingam Devalingam
机构信息
Department of Medicine, Northwestern University, Chicago, IL, USA.
出版信息
J Gastrointest Oncol. 2018 Feb;9(1):143-159. doi: 10.21037/jgo.2018.01.13.
Abstract
Pancreatic adenocarcinoma (PAC) remains one of the leading causes of cancer-related death. Despite multiple advances in targeted and immune therapies, the 5-year survival in advanced PAC remains poor. In this review, we discuss some of the unique aspects of the tumor microenvironment (TME) in PAC that may contribute to its resistance to immune therapies, as well as opportunities to potentially overcome some of these inherent barriers. Furthermore, we discuss strategies to enable immune therapies in PAC such as cytotoxic chemotherapy and radiation therapy, cancer vaccines, cytokine based therapy, oncolytic viruses, and adoptive T-cell therapy. Finally, we address a variety of targeted therapies as a strategy to further amplify immune responses in PAC.
摘要
胰腺腺癌（PAC）仍然是癌症相关死亡的主要原因之一。尽管在靶向治疗和免疫治疗方面取得了多项进展，但晚期PAC的5年生存率仍然很低。在本综述中，我们讨论了PAC肿瘤微环境（TME）的一些独特方面，这些方面可能导致其对免疫治疗产生抗性，以及潜在克服其中一些固有障碍的机会。此外，我们还讨论了在PAC中实施免疫治疗的策略，如细胞毒性化疗和放射治疗、癌症疫苗、基于细胞因子的治疗、溶瘤病毒和过继性T细胞治疗。最后，我们探讨了各种靶向治疗方法，作为进一步增强PAC免疫反应的策略。
相似文献
1
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response.胰腺癌的免疫疗法——克服反应障碍
J Gastrointest Oncol. 2018 Feb;9(1):143-159. doi: 10.21037/jgo.2018.01.13.
2
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌免疫治疗的进展
Cancers (Basel). 2023 Aug 25;15(17):4265. doi: 10.3390/cancers15174265.
3
CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.CD40L 武装溶瘤单纯疱疹病毒通过促进同种小鼠模型中有利于细胞毒性 T 细胞反应的肿瘤微环境来抑制胰腺导管腺癌。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-003809.
4
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告。那不勒斯，2015年12月1日至4日
J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y.
5
Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.用于胰腺导管腺癌的下一代免疫疗法：探索免疫抵抗的途径。
Cancer Metastasis Rev. 2021 Sep;40(3):837-862. doi: 10.1007/s10555-021-09981-3. Epub 2021 Sep 30.
6
Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.自然杀伤 T 细胞免疫疗法联合表达 IL-15 的溶瘤病毒治疗和 PD-1 阻断介导胰腺肿瘤消退。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-003923.
7
Advances in Pancreatic Ductal Adenocarcinoma Treatment.胰腺导管腺癌治疗进展
Cancers (Basel). 2021 Nov 3;13(21):5510. doi: 10.3390/cancers13215510.
8
Immunotherapy for pancreatic cancer: A 2020 update.胰腺癌的免疫治疗：2020 年更新。
Cancer Treat Rev. 2020 Jun;86:102016. doi: 10.1016/j.ctrv.2020.102016. Epub 2020 Mar 25.
9
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.过继性细胞疗法与溶瘤病毒疗法联合应用的机遇与挑战
Mol Ther Oncolytics. 2023 May 4;29:118-124. doi: 10.1016/j.omto.2023.04.008. eCollection 2023 Jun 15.
10
Viro-immune therapy: A new strategy for treatment of pancreatic cancer.病毒免疫疗法：一种治疗胰腺癌的新策略。
World J Gastroenterol. 2016 Jan 14;22(2):748-63. doi: 10.3748/wjg.v22.i2.748.
引用本文的文献
1
Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌错配修复缺陷的临床意义
Cancer Med. 2025 May;14(10):e70960. doi: 10.1002/cam4.70960.
2
Advancing Immunotherapy in Pancreatic Cancer.推进胰腺癌的免疫疗法。
Int J Mol Sci. 2024 Oct 28;25(21):11560. doi: 10.3390/ijms252111560.
3
AVL-armed oncolytic vaccinia virus promotes viral replication and boosts antitumor immunity via increasing ROS levels in pancreatic cancer.携带AVL的溶瘤痘苗病毒通过提高胰腺癌中的活性氧水平促进病毒复制并增强抗肿瘤免疫力。
Mol Ther Oncol. 2024 Sep 17;32(4):200878. doi: 10.1016/j.omton.2024.200878. eCollection 2024 Dec 19.
4
Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study.免疫疗法联合放化疗可改善IV期食管癌患者的总生存期：一项队列研究
Gastro Hep Adv. 2023 Dec 12;3(3):302-310. doi: 10.1016/j.gastha.2023.12.004. eCollection 2024.
5
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel.体细胞突变谱作为不可切除胰腺导管腺癌接受FOLFIRINOX和吉西他滨纳米白蛋白结合型紫杉醇治疗的治疗反应和生存预测指标
Cancers (Basel). 2024 Aug 1;16(15):2734. doi: 10.3390/cancers16152734.
6
The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model.肿瘤基质影响 PDAC 芯片模型中免疫细胞的分布和募集。
Front Immunol. 2023 May 2;14:1155085. doi: 10.3389/fimmu.2023.1155085. eCollection 2023.
7
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma.不可逆电穿孔增强β-葡聚糖诱导的训练性先天免疫治疗胰腺导管腺癌。
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006221.
8
Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors.使用粘着斑激酶抑制剂联合G47Δ和免疫检查点抑制剂克服富含基质的胰腺癌的耐药性。
Mol Ther Oncolytics. 2022 Dec 7;28:31-43. doi: 10.1016/j.omto.2022.12.001. eCollection 2023 Mar 16.
9
Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model.免疫检查点阻断增强了同基因胰腺肿瘤模型中的化学光热疗法。
APL Bioeng. 2022 Sep 23;6(3):036105. doi: 10.1063/5.0099811. eCollection 2022 Sep.
10
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.胰腺导管腺癌中的肿瘤微环境：免疫治疗的意义。
World J Gastroenterol. 2022 Jul 21;28(27):3297-3313. doi: 10.3748/wjg.v28.i27.3297.
本文引用的文献
1
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.依匹单抗联合吉西他滨治疗晚期胰腺癌的 Ib 期研究。
Oncologist. 2020 May;25(5):e808-e815. doi: 10.1634/theoncologist.2019-0473. Epub 2019 Nov 19.
2
Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.胰腺导管腺癌的长期幸存者中 KRAS、TP53 和 SMAD4 的基因突变率较低。
Cancer Biomark. 2018 Feb 6;21(2):323-334. doi: 10.3233/CBM-170464.
3
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
4
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin.转化生长因子-β在胰腺癌起始与进展中的作用：同一硬币的两面
Cell Biosci. 2017 Aug 7;7:39. doi: 10.1186/s13578-017-0168-0. eCollection 2017.
5
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.集落刺激因子 1 受体（CSF1R）抑制剂在癌症治疗中的应用。
J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y.
6
Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.放射治疗在胰腺腺癌治疗中的应用：当前证据综述与未来机遇
Chin Clin Oncol. 2017 Jun;6(3):28. doi: 10.21037/cco.2017.06.12.
7
Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.胰腺癌的免疫疗法：通过新型联合疗法释放其潜力。
World J Clin Oncol. 2017 Jun 10;8(3):230-240. doi: 10.5306/wjco.v8.i3.230.
8
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).帕博利珠单抗联合化疗用于晚期癌症患者的Ib期研究（PembroPlus）。
Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6.
9
Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance.胰腺癌中免疫疗法的应用：明确应答和耐药机制
Am Soc Clin Oncol Educ Book. 2017;37:267-278. doi: 10.1200/EDBK_175232.
10
Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy.CXCL12/CXCR4 轴在胰腺癌进展和治疗中的新作用。
Pharmacol Ther. 2017 Nov;179:158-170. doi: 10.1016/j.pharmthera.2017.05.012. Epub 2017 May 23.
Zotero 插件